ClinicalTrials.gg
CompletedNCT02931747Updated Aug 18, 2017

Effect of Bacopa Monnieri on Working Memory and Cognitive Processing in Student

A Phase 1 interventional study of Placebo and Bacopa Monnieri 300 mg/day in Healthy, sponsored by Khon Kaen University. Completed at 1 site in Thailand. Open to participants aged 15 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-08-18.

Sponsored by Khon Kaen University · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
15 Years to 18 Years
Sex
All
01

Study summary

The purpose of this study is to determine the effect of Bacopa Monnieri on working memory and cognitive processing in student.

Read the detailed description

Learning and working memory are two of the key role for studying and work successful for student particular the high school student who study hard and preparing themselves for the graduate study. The consumption of brain booster product or functional food for improving memory has gained much attention. It has been reported that Bacopa Monnieri could improve learning and working memory in elderly subject by improving the N100 and P300 event related potential. Therefore, Bacopa Monnieri might be the potential product for improving the learning and working memory in student particular high school student.

02

Conditions studied

  • Healthy

Keywords

  • Bacopa Monnieri
  • Working memory
  • Cognitive processing
  • Student
03

In context

Lead sponsor

Khon Kaen University is the lead sponsor of 161 studies on the registry; 24 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy student subject aged between 15-18 years old who studying in the school within Khon Kaen province.
  • is between 18.5-24.9

Exclusion criteria

Exclusion Criteria:

  • Subjects who are diagnosed with one of the following: cardiovascular diseases, respiratory disease, neuropsychological diseases, head injury, diabetes mellitus, liver disease, cancer, disease and hematological disorder are excluded.
  • Subjects who take any medicine or nutraceuticals or hormone that effect on central nervous system are excluded.
  • Alcohol addict or smoking addiction (more than 10 pieces/day)
  • Athlete or subjects who have a regular exercise more than 3 times/week
  • Subjects who don't follow the instruction during the trial
  • Subjects who are participating the other project.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
75 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Subjects are received the pill of placebo which has same color, shape and smell like the Bacopa Monnieri once daily for 16 weeks.

    Dietary Supplement: Placebo

  • Active comparator
    Bacopa Monnieri 300 mg/day

    Subjects are received the pill of Bacopa Monnieri at the dose of 300 mg/day once daily for 16 weeks

    Dietary Supplement: Bacopa Monnieri 300 mg/day

  • Active comparator
    Bacopa Monnieri 600 mg/day

    Subjects are received the pill of Bacopa Monnieri at the dose of 600 mg/day once daily for 16 weeks

    Dietary Supplement: Bacopa Monnieri 600 mg/day

Interventions

  • Dietary supplementPlacebo

    Subjects are received Placebo once daily for 16 weeks.

  • Dietary supplementBacopa Monnieri 300 mg/day

    Drug page: Bacopa monnieriStudies of Bacopa monnieriBacopa monnieri pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects are received Bacopa Monnieri at the dose of 300 mg/day once daily for 16 weeks.

  • Dietary supplementBacopa Monnieri 600 mg/day

    Drug page: Bacopa monnieriStudies of Bacopa monnieriBacopa monnieri pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects are received Bacopa Monnieri at the dose of 600 mg/day once daily for 16 weeks.

06

What researchers measure

Primary outcomes

  1. Cognitive processing using the latency of P300 wave

    The latency of P300 wave was measured and expressed as millisecond.

    Time frame: 4 months

  2. Cognitive processing using the amplitude of P300 wave

    The amplitude of P300 wave was measured and expressed as micro-volt.

    Time frame: 4 months

  3. Attention using the latency of N100 wave

    The latency of N100 wave was measured and expressed as millisecond.

    Time frame: 4 months

  4. Attention using the amplitude of N100 wave

    The amplitude of N100 wave was measured and expressed as micro-volt.

    Time frame: 4 months

Secondary outcomes

  1. Accuracy of working memory using computerized battery test

    The accuracy of working memory was determined and expressed as percentage.

    Time frame: 4 months

  2. Speed of working memory using computerized battery test

    The speed of working memory was determined and expressed as millisecond.

    Time frame: 4 months

  3. Assessment of psychiatric symptoms using the symptom check list 90 (SCL-90)

    Time frame: 4 months

  4. Assessment of mood scale using Bond-Lader visual analogue scales

    Time frame: 4 months

  5. Acetylcholinesterase activity in serum

    Time frame: 4 months

  6. Monoamine oxidase activity in serum

    Time frame: 4 months

  7. Glutamic acid decarboxylase (GAD) activity in serum

    Time frame: 4 months

  8. Gamma-aminobutyric acid (GABA)-transaminase in serum

    Time frame: 4 months

  9. Malondialdehyde level in serum

    Time frame: 4 months

  10. Activity of superoxide dismutase in serum

    Time frame: 4 month

  11. Activity of catalase in serum

    Time frame: 4 month

  12. Activity of glutathione peroxidase in serum

    Time frame: 4 month

  13. Consumption safety of Bacopa Monnieri using electrocardiogram (EKG)

    Time frame: 4 month

  14. Consumption safety of Bacopa Monnieri using hematological values .

    The hematological values including red blood cell, white blood cell, hematocrit and platelet were determined and the data was expressed as number of subject presented with abnormal hematological value.

    Time frame: 4 month

  15. Consumption safety of Bacopa Monnieri using blood chemistry

    The blood chemistry values including renal function test, liver function test, lipid profile, electrolytes and glucose were determined and the data was expressed as number of subject presented with abnormal blood chemistry value.

    Time frame: 4 month

  16. Consumption safety of Bacopa Monnieri using blood pressure measurement

    Time frame: 4 month

07

Study locations

1 site
  • Jitanaporn Wattanathorn
    Khon Kaen, 40002, Thailand
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2016, a primary completion of Mar 2017 and a completion of Mar 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2016
First posted
Oct 13, 2016
Start
Jul 2016
Primary completionActual
Mar 2017
CompletionActual
Mar 2017
Last update
Aug 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02931747
Collaborators
Government Pharmaceutical Organization
Responsible party
Jintanaporn Wattanathorn (Associated Professor Doctor, Khon Kaen University) — Principal investigator
First posted
Oct 13, 2016
Start date
Jul 2016
Primary completion
Mar 2017
Completion
Mar 2017
Last update
Aug 18, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bacopa monnieri

Start the discussion